Innovation in Released August 6, ARM’s H1 2020 Global Regenerative Medicine & Advanced Therapies Sector Report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic. The sector is poised for record-breaking financings in 2020, with several notable policy wins in the first half. Most importantly, patients are continuing to benefit from these transformative therapies.
Recordings Available: ARM’s Cell & Gene Webinar Series
This spring, ARM hosted experts on biotech fundraising, market access, value-based therapies, clinical trials amidst the pandemic, and cell therapies to treat COVID-19 as a part of a webinar series on timely sector issues.
Manufacturing Cures: A Roadmap for the Development of Gene Therapies
Senior ARM representatives Janet Lambert, CEO, and Michael Lehmicke, Director, Science & Industry Affairs, provide insights on the upcoming publication of A-Gene, a case-study based guide on applying Quality-by-Design principles to the development of gene therapies.
Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
Produced by the Marwood Institute and funded by ARM, this report uses a “Transformative Therapy Value Model,” and demonstrates that durable cell or gene therapies for multiple myeloma, sickle cell disease, and hemophilia A could provide cumulative cost-savings of $33B over the next ten years.
Companies Developing Regenerative Medicines for Rare Disease Raise $6.4B in 2019
ARM’s 2019 rare disease report provides an overview of gene therapy, cell therapy, & tissue engineering therapeutic companies active in developing therapies for rare diseases. The report also provides a breakdown of the 647 clinical trials in rare diseases utilizing regenerative medicine technologies.
Potentially curative cell and gene therapies are changing the face of medicine and providing hope to patients where there was once none. But how will they be paid for? This webinar discusses the implementation of value-based payment models for innovative therapies.
This webinar highlights potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, presented on their treatment approaches and plans for near term clinical trials.
ARM’s annual State of the Industry briefing provides an update on global financings, clinical development, public policy considerations, and other regenerative medicine sector trends. A recording of the presentation is available here.